CMS plan to slash $1.6 billion from 340B program will reduce discounts on cancer drugs

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Hospitals enrolled in the 340B program stand to lose up to $1.6 billion in Medicare Part B reimbursements through upcoming cuts to the drug pricing program, according to a final rule by the Centers for Medicare and Medicaid Services.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

President Joe Biden April 9 announced his FY2022 budgetary plans for ARPA-H—Advanced Research Projects Agency-Health—a federal entity designed to “deliver breakthroughs to find cures for cancer and other diseases.” In his initial White House budget proposal—dubbed skinny budget, or budget-lite—Biden is requesting $6.5 billion to fund ARPA-H.  “The discretionary request calls for $6.5 billion to...

Associate Editor